Eastern Cooperative Oncology Group

描述（由申请人提供）：贝斯以色列女执事医疗中心（BIDMC）是1996年贝斯以色列和新英格兰女执事医院合并的结果，这两个医院是朗伍德医疗区的两个邻居和主要的哈佛医学院机构。BIDMC教师由一群特殊的临床医生和基础及临床研究人员组成。贝斯以色列女执事癌症中心包含10个多学科临床和临床研究项目。其中一些已经获得了国家的认可，包括那些专注于乳腺癌，黑色素瘤，肾癌，前列腺癌，血液和肝脏恶性肿瘤。BIDCC的科学专业领域包括：疫苗和细胞因子治疗，血管生成和信号转导抑制，成像和射频消融，基因组学和早期疾病的管理。1999年，BIDMC参与了Dana-Farber/哈佛癌症中心（DF/HCC）的成立，该中心包括所有哈佛医学院附属机构：BIDMC、Dana-Farber癌症研究所、布里格姆妇女医院、马萨诸塞州总医院、儿童医院医疗中心、哈佛医学院和哈佛公共卫生学院。DF/HCC的相互作用大大增加了所有参与机构进行转化研究的机会，促进了针对乳腺癌、皮肤癌、肾癌、前列腺癌、卵巢癌、肺癌和骨髓瘤的SPORE赠款的成功竞争，以及许多研究者发起的研究方案的制定。这些转化研究项目正在形成几个拟议的和未来的合作小组试验或相关的相关科学工作的基础。自1997年以来，BIDMC一直是ECOG的主要成员机构，并非常致力于临床癌症研究。 BIDCC研究者每年招募近700例患者，超过150例治疗性和非治疗性患者，其中平均每年有70例患者参加ECOG申办或批准的治疗性试验。临床研究职能由集中的癌症临床试验办公室提供支持。许多研究者在ECOG委员会和试验设计中变得越来越活跃，预计随着BIDMC成为ECOG的更高级成员，这种活动将继续增长。

DESCRIPTION (provided by applicant): Beth Israel Deaconess Medical Center (BIDMC) resulted from the 1996 merger of the Beth Israel and New England Deaconess Hospitals, two neighbors and major Harvard Medical School institutions in the Longwood Medical area. The BIDMC faculty consists of an exceptional group of committed,clinicians and basic and clinical researchers. The Beth Israel Deaconess Cancer Center contains 10 multidisciplinary clinical and clinical reseawrch programs. Several of these have achieved national recognition including those focusing on breast cancer, melanoma, renal cancer, prostate cancer, hematologic and hepatic malignancies. Areas of scientific expertise within BIDCC include: vaccine and cytokine therapy, angiogenesis and signal transduction inhibition, imaging and radiofrequency ablation, genomics and management of early stage disease. In 1999, the BIDMC participated in the founding of the Dana-Farber/Harvard Cancer Center (DF/HCC), which includes all Harvard Medical School affiliated institutions: BIDMC, Dana-Farber Cancer Institute, Brigham and Woman's Hospital, Massachusetts General Hospital, Children's Hospital Medical Center, Harvard Medical School and Harvard School of Public Health. The DF/HCC interactions have greatly enhanced the opportunities for translational research across all the participating institutions, facilitating the successful competition for SPORE grants focused on Breast, Skin, Renal, Prostate, Ovarian, and Lung Cancers and Myeloma and the development of many investigator- initiated research protocols. These translational research projects are forming the basis several proposed and future cooperative group trials or related correlative science efforts. BIDMC has been a main member institution of ECOG ince 1997 and is very committed to clinical cancer research. BIDCC investigators have accrued almost 700 patients per year to over 150 therapeutic and nontherapeutic including an average of 70 patients annually to therapeutic trials sponsored or endorsed by ECOG. Clinical research functions are supported by a centralized the Cancer Clinical Trials Office. Many investigators are becoming increasing active in ECOG committees and in trial design and it is anticipated that this activity will continue to grow as BIDMC becomes a more senior member of the ECOG.